Myrcludex B: Completed Phase IIa enrollment

Hepatera completed enrollment of 48 patients who are negative for hepatitis B e antigen (HBeAg) in an open-label, Russian Phase IIa trial comparing 0.5, 1 and 2 mg subcutaneous Myrcludex B daily for 1...